Valeant Pharma Gets a Buy Rating from Cantor Fitzgerald

By Ryan Adsit

In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Valeant Pharma (NYSE: VRX), with a price target of $23. The company’s shares opened today at $16.80.

According to, Chen is ranked 0 out of 5 stars with an average return of -7.0% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc.

Currently, the analyst consensus on Valeant Pharma is Hold and the average price target is $17.33, representing a 3.2% upside.

In a report issued on July 19, Stifel Nicolaus also reiterated a Buy rating on the stock with a $35 price target.

The company has a one year high of $32.75 and a one year low of $8.31. Currently, Valeant Pharma has an average volume of 23.25M.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. It operates through the following segments: The Bausch + Lomb/International, The Branded Rx, and The U.S.